

Brain/Spinal Cord

**Protocol applies to all neoplasms of the brain/spinal cord.
Excludes neoplasms of the pituitary gland.**

*Protocol revision date: January 2004
No AJCC/UICC staging system*

Procedures

- **Cytology** (No Accompanying Checklist)
- **Biopsy**
- **Resection**

Authors

Gary S. Pearl, MD, PhD

Department of Pathology, Orlando Regional Healthcare System, Orlando, Florida

Saeid Movahedi-Lankarani, MD

Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland

Previous contributors: Nancy C. Karpinski, MD; Kyung-Whan Min, MD;
Steven C. Bauseman, MD; Lawrence A. Hansen, MD; Charles Kerber, MD

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2004
Applies to all brain/spinal cord neoplasms
Excludes neoplasms of the pituitary gland
No AJCC/UICC staging system*

BRAIN/SPINAL CORD: Biopsy/Resection

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Specimen Type**

- Open biopsy
 Stereotactic needle core biopsy
 Subtotal/partial resection
 Total resection
 Other (specify): _____
 Not specified

Specimen Size

Greatest dimension: ___ cm

*Additional dimensions: ___x___ cm

Tumor Site (check all that apply)

- Cerebral meninges
 Cerebrum (specify lobe[s], if known): _____
 Basal ganglia
 Thalamus
 Hypothalamus
 Suprasellar
 Pineal
 Cerebellum
 Cerebellopontine angle
 Ventricle
 Brain stem
 Spinal cord
 Nerve root
 Other (specify): _____
 Not specified

2

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Tumor Size

Largest dimension: ___ cm

*Additional dimensions: ___x___ cm

___ Cannot be determined (see Comment)

MICROSCOPIC**Histologic Type**

- Astrocytoma, not otherwise characterized
- Astrocytoma, diffuse
- Astrocytoma, pilocytic
- Astrocytoma, pleomorphic xanthoastrocytoma
- Astrocytoma, anaplastic
- Astrocytoma, other (specify): _____
- Glioblastoma
- Gliosarcoma
- Oligodendroglioma, not otherwise characterized
- Oligodendroglioma, anaplastic
- Oligoastrocytoma, not otherwise characterized
- Oligoastrocytoma, anaplastic
- Ependymoma, not otherwise characterized
- Ependymoma, tanycytic
- Ependymoma, myxopapillary
- Ependymoma, anaplastic
- Ependymoma, other (specify): _____
- Subependymoma
- Choroid plexus papilloma
- Choroid plexus carcinoma
- Gangliocytoma
- Ganglioglioma
- Dysembryoplastic neuroepithelial tumor
- Desmoplastic infantile ganglioglioma/astrocytoma
- Pineocytoma
- Pineoblastoma
- Pineal parenchymal tumor of intermediate differentiation
- Medulloblastoma, not otherwise characterized
- Medulloblastoma, desmoplastic
- Medulloblastoma, large cell
- Medulloblastoma, melanotic
- Medulloblastoma, other (specify): _____
- Primitive neuroectodermal tumor (PNET)
- Neuroblastoma
- Atypical teratoid/rhabdoid tumor
- Schwannoma, not otherwise characterized
- Schwannoma, cellular
- Schwannoma, plexiform
- Schwannoma, melanotic

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

- Schwannoma, other (specify): _____
 Neurofibroma, not otherwise characterized
 Neurofibroma, plexiform
 Malignant peripheral nerve sheath tumor (MPNST), not otherwise characterized
 Malignant peripheral nerve sheath tumor (MPNST), epithelioid
 Malignant peripheral nerve sheath tumor (MPNST), melanotic
 Malignant peripheral nerve sheath tumor (MPNST), other
 (specify): _____
 Meningioma, not otherwise characterized
 Meningioma, atypical
 Meningioma, papillary
 Meningioma, rhabdoid
 Meningioma, chordoid
 Meningioma, clear cell
 Meningioma, anaplastic
 Meningioma, other (specify): _____
 Malignant lymphoma (specify type): _____
 Hemangioblastoma
 Craniopharyngioma, not otherwise characterized
 Craniopharyngioma, adamantinomatous
 Craniopharyngioma, papillary
 Craniopharyngioma, other (specify): _____
 Germinoma
 Embryonal carcinoma
 Yolk sac tumor
 Choriocarcinoma
 Teratoma, mature
 Teratoma, immature
 Teratoma with malignant transformation
 Mixed germ cell tumor (specify): _____
 Other(s) (specify): _____
 Malignant neoplasm, type cannot be determined

Histologic Grade

- Not applicable
 Cannot be determined
 WHO Grade I
 WHO Grade II
 WHO Grade III
 WHO Grade IV
 Other (specify): _____

Margins

- Cannot be assessed
- Not applicable
- Margins uninvolved by tumor
- Margin(s) involved by tumor
Specify which margin(s): _____

***Additional Studies (check all that apply)**

- * None performed
- * Electron microscopy
- * Cytogenetics
- * Molecular testing (specify): _____
- * Other (specify): _____

***Additional Pathologic Findings**

*Specify: _____

***Comment(s)**

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Background Documentation

Protocol revision date: January 2004

I. Cytologic Material

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (Note **B**)
 - c. Clinical/imaging differential diagnosis
 - d. Procedure (eg, percutaneous fine-needle aspiration)
 - e. Anatomic site of specimen (Note **C**)

B. Macroscopic Examination

1. Specimen
 - a. Unfixed/fixed (specify fixative) (Note **D**)
 - b. Number of slides received, if appropriate
 - c. Cytologic preparation of tissue specimen (touch or squash/smear preparation)
2. Material submitted for microscopic evaluation (eg, smear of fluid, other liquid based cytology preparations, cell block) (Note **E**)
3. Special studies (eg, cytochemistry, immunocytochemistry, microbiology, flow cytometry, genetic and molecular testing) (Note **F**)

C. Microscopic Evaluation

1. Adequacy of specimen for diagnostic evaluation (if unsatisfactory or limited, specify reason)
2. Tumor
 - a. Histologic type, if possible (Note **G**)
3. Other pathologic findings
4. Results/status of special studies (specify)
5. Comments
 - a. Correlation with intra-procedural consultation
 - b. Correlation with other specimens
 - c. Correlation with clinical information (Note **H**)

II. Biopsy

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure

4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (Note **B**)
 - c. Clinical/imaging differential diagnosis
 - d. Procedure (eg, stereotactic needle core biopsy, open biopsy)
 - e. Anatomic site of specimen (Note **C**)

B. Macroscopic Examination

1. Specimen
 - a. Unfixed/fixed (specify fixative) (Note **D**)
 - b. Size (number of cores or size of biopsy in dimensions or approximate volume)
 - c. Descriptive features (grossly obvious meninges, gray matter or white matter, color, texture, cut surface, mucinous, fibrous, bloody, necrotic, gritty)
 - d. Recognition of gross and microscopic correlates is helpful in correct interpretation of microscopic findings and is also helpful in selecting cores for frozen section analysis
2. Special studies (Note **F**)
 - a. Frozen sections, if requested
 - b. Squash, touch, or scrape preparations
 - c. Histochemistry
 - d. Immunohistochemistry, including proliferation markers
 - e. Electron microscopy (EM)
 - f. Other (microbiology, flow cytometry, cytogenetics, molecular diagnostics)
 - g. Was a portion of tissue frozen for later potential studies?
3. Tissue submitted for microscopic evaluation. The specimen is usually totally submitted after removing tissue for frozen sections, EM, or other special studies as indicated in Note **F**. Try to orient at right angles to surface.

C. Microscopic Evaluation

1. Tumor
 - a. Histologic type (Note **I**)
 - b. Histologic grade (Note **J**)
 - c. Additional features, if present
 - (1) hemosiderin deposition
 - (2) calcification
 - (3) microcyst formation
 - (4) mitotic activity
 - (5) pleomorphism
 - (6) presence of gemistocytes
 - (7) vascular proliferation
 - (8) necrosis
 - (9) eosinophilic granular bodies
 - d. Findings in smear/squash, touch, or scrape preparations (Note **K**)
2. Status/results of special studies (specify)
3. Comments
 - a. Correlation with intraoperative consultation
 - b. Correlation with previous specimens
 - c. Correlation with clinical and radiographic information (Note **H**)

III. Resection

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (Note **B**)
 - c. Clinical/imaging differential diagnosis
 - d. Procedure (total, subtotal, or partial resection)
 - e. Operative findings
 - f. Anatomic site of specimen (Note **C**)

B. Macroscopic Examination

1. Specimen
 - a. Unfixed/fixed (specify fixative) (Note **D**)
 - b. Number of pieces with combined aggregate dimensions (the extent of resection can have prognostic significance) (Note **A**)
 - c. Descriptive features (grossly obvious meninges, gray matter or white matter, color, texture, cut surface, mucinous, fibrous, bloody, necrotic, gritty)
 - d. Recognition of gross and microscopic correlates is helpful in correct interpretation of microscopic findings and is also helpful in selecting cores for frozen section analysis
 - e. Margins, as appropriate. For the majority of central nervous system (CNS) neoplasms, margins are not evaluated because specimens are fragmented. Exceptions would be some meningeal or metastatic tumors.
 - f. Results of intraoperative consultation
2. Tissue submitted for microscopic evaluation. The specimen is usually totally submitted after removing tissue for frozen sections, EM, or special studies as suggested in Note **F**.
3. Special studies (Note **F**)
 - a. Frozen sections, if requested
 - b. Squash/smear, touch, or scrape preparations
 - c. Histochemistry
 - d. Immunohistochemistry, including proliferation markers
 - e. Electron microscopy (EM)
 - f. Receptor analysis
 - g. Other (microbiology, flow cytometry, cytogenetics, molecular diagnostics)
 - h. Was a portion of tissue frozen for later potential studies?

C. Microscopic Evaluation

1. Tumor
 - a. Histologic type (Note **I**)
 - b. Histologic grade (Note **J**)
 - c. Local extension (eg, bony or soft tissue invasion, subarachnoid spread) (Note **K**)
 - d. Additional features, if present
 - (1) hemosiderin deposition
 - (2) calcification

- (3) microcyst formation
- (4) mitotic activity
- (5) pleomorphism
- (6) presence of gemistocytes
- (7) vascular proliferation
- (8) necrosis
- (9) eosinophilic granular bodies
- e. Findings in squash, touch, or scrape preparations (Note **K**)
2. Status/results of special studies (specify)
3. Comments
 - a. Correlation with intraoperative consultation
 - b. Correlation with previous specimens
 - c. Correlation with clinical and radiographic information (Note **H**)

Explanatory Notes

A. Relevant History

Patient Age

Most central nervous system (CNS) tumors show an age predilection, and patient age has been shown to predict survival in many malignant CNS neoplasms. With diffusely infiltrating astrocytic tumors, age followed by histologic grade represent the 2 strongest prognostic indicators for patient outcome, with patient age of greater than 50 years and high-grade tumors serving as negative indicators.¹⁻⁴

Duration of Symptoms (Acute or Chronic)

A long clinical history of CNS symptoms or seizures prior to the diagnosis of a CNS tumor favors a slowly growing neoplasm that is more likely to be benign. A rapidly progressive neurological deficit of sudden onset is more consistent with, but not always indicative of, a high-grade malignant tumor.⁵

Extent of Resection

For most CNS tumors, the amount of tumor removed (total, subtotal, or partial resection) is an important predictor of patient outcome.^{3,4,6} The extent of resection can be estimated by recording the gross dimensions of the aggregate pieces. In most operating rooms, a suction device is frequently used in conjunction with gross debulking to remove tumors. The tissue in the suction bags generally liquefies and is not usually adequate for surgical pathology submission. However, when possible, we recommend that the surgical team be encouraged to submit the suction specimen to surgical pathology. This will serve to better estimate the extent of resection, and the tissue present in the suction specimen might be critical in making the correct diagnosis.

Tumor Location and Size

The extent of surgical resection possible is determined by tumor location and size.

Previous Diagnoses

Knowledge of the presence or absence of extracranial disease, ie, a history of immunosuppression or a history of a primary malignant neoplasm outside the CNS, can be critical in the correct interpretation of biopsy material.⁵ If a metastatic tumor is included in the differential diagnosis, it is helpful to have slides of the primary tumor available.

Previous CNS Biopsies

Previous slides should be obtained whenever possible for comparison.

History of Radiation or Radiosurgery

Knowledge of prior radiation therapy or radiosurgery can help in interpreting specimens in which there are large areas of radiation change (eg, coagulative necrosis, gliosis, vascular hyalinization).⁷ CNS tumors noted to arise in a field of prior irradiation include meningiomas, meningeal sarcomas, astrocytomas, primitive neuroectodermal tumors, and gliosarcomas.⁸ Radiation therapy of diffusely infiltrating astrocytomas has been shown to increase survival.^{3,9}

Family History of Cancer or Primary CNS Tumors

Approximately 16% of patients with brain tumors have a family history of cancer. Several genetic conditions/syndromes are associated with an increased predisposition to the development of certain brain neoplasms. Neurofibromatosis type 2 is associated with acoustic neuromas, multiple meningiomas, and spinal cord ependymomas. Tuberous sclerosis is associated with subependymal giant cell astrocytomas. Von Hippel-Lindau is associated with hemangioblastomas of the cerebellum while Turcot syndrome is associated with medulloblastomas and glioblastomas. Therefore, knowledge of presence of such conditions is important in reaching a proper diagnosis.

B. Relevant Findings**Imaging Features**

- Density
- Enhancement pattern
- Well-circumscribed or infiltrative borders
- Cyst formation
- Calcification
- Location (intraventricular; white matter, gray matter, or both)

Recognition of characteristic imaging patterns and locations of CNS tumors is important in correct interpretation of biopsy specimens, eg, low-grade infiltrating astrocytomas usually do not enhance, whereas high-grade ones do.^{5,10,11} Tumor enhancement and peritumoral edema in infiltrating astrocytomas are associated with a worse prognosis, and diffuse tumors have been shown to have a poorer prognosis than focal ones.^{12,13}

C. Anatomic Site of Specimen**Cytologic Material**

- Cerebrospinal fluid (CSF) (ventricular, lumbar, cisternal)
- Cyst fluid
- Fine-needle aspiration
- Percutaneous (specify site)
- Stereotactic computer tomography (CT)-guided
- Other (eg, external shunt drain canisters)

Biopsy or Resection

- Dura (convexity, falx, tentorium, sphenoid wing, skull base)
- Leptomeninges
- Cerebrum (specify lobe: frontal, parietal, temporal, occipital)
- Basal ganglia
- Thalamus

Hypothalamus
Pituitary
Suprasellar area
Pineal
Cerebellum (specify lobe: right or left hemisphere, midline or lateral)
Cerebellopontine angle
Ventricle (third, lateral, fourth)
Brain stem (midbrain, pons, or medulla)
Spine (extradural, intradural/extramedullary, intradural/intramedullary, conus medullaris, filum terminale)
Nerve root(s)/canal (extradural, intradural, anterior root or posterior root)

D. Specimen Unfixed/Fixed

Cytologic Material

Cytologic preservation in cerebrospinal fluid (CSF) depends on the time interval before processing, especially for hematopoietic and some neuroepithelial cells. Refrigerate if delayed more than 30 to 45 minutes. Record the time interval to aid in interpretation.

Biopsy or Resection

Cellular detail is very important for interpreting CNS neoplasms, and previously frozen tissue is suboptimal, especially for grading and subclassifying gliomas. Recommendations for optimally freezing and cutting frozen sections from tissue from the brain and spinal cord have been made in a previously published paper.⁵ Make every attempt to retain tissue that has not been previously frozen for permanent sections. Avoid using sponges in cassettes because they produce angular defects, which resemble vascular/luminal spaces in the final sections. Wrapping small biopsies in lens paper prior to placing them in cassettes is recommended.⁵

E. Cytologic Material Submitted for Microscopic Evaluation

Cytospin slides or liquid-based monolayer cytology, both air-dried Romanowsky-stained and fixed Papanicolaou-stained slides, as well as unstained slides, should be prepared from fluid specimens, especially CSF, meningeal, and tumoral cyst fluid.

F. Special Studies

It may be necessary to divide biopsy/resection tissue into portions for the following procedures:

1. Squash/smear, touch, or scrape preparations
2. Unfrozen permanent paraffin sections
3. Frozen sections, if requested
4. Electron microscopy (EM) (retain a small portion in 3% glutaraldehyde or "embed and hold" for EM, if necessary)
5. Other (microbiology, flow cytometry, cytogenetics, molecular diagnostics)
6. Frozen tissue, if requested (freeze fresh tissue as soon as possible and store at -70°C), especially for possible future molecular diagnostic studies

When the tissue is a biopsy and the tissue sample is small, the order of priority for processing tissue for the procedures outlined above is as listed. It is imperative to have unfrozen tissue for diagnosis, since freezing artifact may make accurate diagnosis very difficult or impossible. Recommendations for optimally freezing and cutting frozen sections from tissue from the brain and spinal cord have been made in a previously published paper.⁵ If biopsy frozen and permanent sections are nondiagnostic, tissue that

was retained in 3% glutaraldehyde could be submitted for EM or for additional paraffin sections, depending on the amount of tissue available, with the hope of making a diagnosis. Some pathologists may choose to examine semi-thin or 1-micron-thick stained sections with toluidine blue instead.

Squash preparations (also referred to as smear preparations by some experts) are prepared by placing a tiny (1- to 2-mm) fragment of tissue onto a glass slide, placing another glass slide over it, pressing the slides together, squashing the tissue between them, then sliding the 2 slides past each other, dragging squashed tissue across each slide. Slides are then rapidly placed into fixative in the same rack used for frozen sections and stained as for frozen sections.⁵

Squash preparations are recommended for most CNS lesions. Touch preparations are recommended for pituitary adenomas, oligodendrogliomas, meningiomas, metastatic carcinomas, and lymphomas. Scrape preparations, in which tissue is scraped with a scalpel blade and scrapings applied to glass slides and stained similar to squash and touch preparations, are recommended for desmoplastic tumors, such as dural metastases that cannot be squashed or do not shed well on touch preparations.

If infectious etiologies are suspected, a portion of fresh tissue can be sent to the microbiology laboratory in a sterile container to be processed for bacterial, fungal, or viral cultures. Tissue from patients with symptoms suggestive of transmissible spongiform encephalopathy (Creutzfeldt-Jakob disease [CJD]) requires special handling. The infectious agent of CJD may be inactivated by immersing formalin-fixed tissue in 50 to 100 mL of pure formic acid for 1 hour, followed by reimmersion in fresh formalin.¹⁴ While the clinical diagnosis of transmissible spongiform encephalopathy encompasses a spectrum of neurologic dysfunction, rapidly progressive dementia and myoclonus are especially suggestive of this diagnosis.¹⁵

If a lymphoproliferative disorder is suspected, a portion of fresh tissue can be sent to the surgical pathology laboratory where it will be placed in appropriate holding media (RPMI) for flow cytometry and cytogenetics. Refer to a previously published protocol for processing specimens from patients with non-Hodgkin lymphoma.¹⁶

Molecular diagnostic testing is playing an increasingly important role in the diagnosis, staging, and treatment of tumors.¹⁷⁻¹⁹ Tissue that has been frozen shortly after arrival in the laboratory and stored at -70°C will be suitable for these studies. Paraffin-embedded tissue can also occasionally be used.

G. Cytopathology: Histologic Type

Tumor cells, especially those of glial lineage, are often altered by time in fluid/CSF and are difficult to interpret unless cell clusters or tissue fragments are available. Choroid plexus and ependymal cells are quite similar, with the latter showing more "degenerative" cytologic features and fewer cellular clusters. Therefore, the designation "choroid-ependymal" cells is appropriate. Ependymomas and choroid plexus papillomas generally appear cytologically benign or bland. It is helpful to prepare squash preparations routinely during intraoperative consultations to develop or keep a sharp "cytologic eye" for CNS neoplasms.

H. Comments

Correlation of clinical and radiographic information should be critically reviewed before final sign-out of the biopsy diagnosis.²⁰

I. Histologic Type

The World Health Organization (WHO) classification of tumors of the central nervous system is shown below.²¹

WHO Histologic Typing of Tumors of the Nervous System

Tumors of Neuroepithelial Tissue

Astrocytic tumors

- Diffuse astrocytoma
 - Fibrillary astrocytoma
 - Protoplasmic astrocytoma
 - Gemistocytic astrocytoma
- Anaplastic astrocytoma
- Glioblastoma
 - Giant cell glioblastoma
 - Gliosarcoma
- Pilocytic astrocytoma
- Pleomorphic astrocytoma
- Pleomorphic xanthoastrocytoma
- Subependymal giant cell astrocytoma

Oligodendroglial tumors

- Oligodendroglioma
 - Anaplastic oligodendroglioma
- Mixed gliomas
 - Oligoastrocytoma
 - Anaplastic oligoastrocytoma

Ependymal tumors

- Ependymoma
 - Cellular
 - Papillary
 - Clear cell
 - Tanycytic
- Anaplastic ependymoma
- Myxopapillary ependymoma
- Subependymoma

Choroid plexus tumors

- Choroid plexus papilloma
- Choroid plexus carcinoma

Glial tumors of uncertain origin

- Astroblastoma
- Gliomatosis cerebri
- Chordoid glioma of the third ventricle

Neuronal and mixed neuronal-glial tumors

- Gangliocytoma
- Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)
- Desmoplastic infantile astrocytoma/ganglioglioma
- Dysembryoplastic neuroepithelial tumor

- Ganglioglioma
- Anaplastic ganglioglioma
- Central neurocytoma
- Cerebellar liponeurocytoma
- Paranglioma of the filum terminale
- Neuroblastic tumors
 - Olfactory neuroblastoma (esthesioneuroblastoma)
 - Olfactory neuroepithelioma
 - Neuroblastomas of the adrenal gland and sympathetic nervous system
- Pineal parenchymal tumors
 - Pineocytoma
 - Pineoblastoma
 - Pineal parenchymal tumor of intermediate differentiation
- Embryonal tumors
 - Medulloepithelioma
 - Ependymoblastoma
 - Medulloblastoma
 - Desmoplastic medulloblastoma
 - Large cell medulloblastoma
 - Medullomyoblastoma
 - Melanotic medulloblastoma
 - Supratentorial primitive neuroectodermal tumor (PNET)
 - Neuroblastoma
 - Ganglioneuroblastoma
 - Atypical teratoid/rhabdoid tumor

Tumors of Peripheral Nerves

- Schwannoma (Neurilemmoma, Neurinoma)
 - Cellular
 - Plexiform
 - Melanotic
- Neurofibroma
 - Plexiform
- Perineurioma
 - Intraneural perineurioma
 - Soft tissue perineurioma
- Malignant Peripheral Nerve Sheath Tumor (MPNST)
 - Epithelioid
 - MPNST with divergent mesenchymal and/or epithelial differentiation
 - Melanotic
 - Melanotic psammomatous

Tumors of the Meninges

- Tumors of meningotheial cells
 - Meningioma
 - Meningothelial
 - Fibrous (fibroblastic)
 - Transitional (mixed)
 - Psammomatous
 - Angiomatous
 - Microcystic

- Secretory
- Lymphoplasmacyte-rich
- Metaplastic
- Clear cell
- Chordoid
- Atypical
- Papillary
- Rhabdoid
- Anaplastic meningioma
- Mesenchymal, non-meningothelial tumors
 - Lipoma
 - Angiolipoma
 - Hibernoma
 - Liposarcoma (intracranial)
 - Solitary fibrous tumor
 - Fibrosarcoma
 - Malignant fibrous histiocytoma
 - Leiomyoma
 - Leiomyosarcoma
 - Rhabdomyoma
 - Rhabdomyosarcoma
 - Chondroma
 - Chondrosarcoma
 - Osteoma
 - Osteosarcoma
 - Osteochondroma
 - Haemangioma
 - Epithelioid haemangioendothelioma
 - Haemangiopericytoma
 - Angiosarcoma
 - Kaposi sarcoma
- Primary melanocytic lesions
 - Diffuse melanocytosis
 - Melanocytoma
 - Malignant melanoma
 - Meningeal melanomatosis
- Tumors of uncertain histogenesis
 - Haemangioblastoma

Lymphomas and Haemopoietic Neoplasms

- Malignant lymphomas
- Plasmacytoma
- Granulocytic sarcoma

Germ Cell Tumors

- Germinoma
- Embryonal carcinoma
- Yolk sac tumor (endodermal sinus tumor)
- Choriocarcinoma

Teratoma

Mature

Immature

Teratoma with malignant transformation

Mixed germ cell tumors

Tumors of the Sellar Region

Craniopharyngioma

Adamantinomatous

Papillary

Granular cell tumor

Metastatic Tumors**J. Histologic Grade**

The WHO grading system (malignancy scale) of CNS tumors is shown below.²¹ There is no formal TNM-based classification and staging system for the central nervous system at this time.²²⁻²³

Tumor Group	Tumor Type	Grade I	Grade II	Grade III	Grade IV
Astrocytic tumors	Subependymal giant cell	X			
	Pilocytic	X			
	Pleomorphic xanthoastrocytoma		X		
	Diffuse infiltrating		X		
	Anaplastic infiltrating Glioblastoma			X	X
Oligodendrogliomas	Low-grade		X		
	Anaplastic			X	
Oligoastrocytoma	Low-grade		X		
	Anaplastic			X	
Ependymal tumors	Subependymoma	X			
	Myxopapillary	X			
	Low-grade		X		
	Anaplastic			X	
Choroid plexus tumors	Papilloma	X			
	Carcinoma			X	X

Tumor Group	Tumor Type	Grade I	Grade II	Grade III	Grade IV
Neuronal / glial tumors	Gangliocytoma	X			
	Ganglioglioma	X	X		
	Desmoplastic infantile ganglioglioma / astrocytoma	X			
	Dysembryoplastic neuroepithelial tumor	X			
	Central neurocytoma		X		
Pineal tumors	Pineocytoma		X		
	Pineocytoma / pineoblastoma			X	X
	Pineoblastoma				X
Embryonal tumors	Medulloblastoma				X
	Other primitive neuroectodermal tumors				X
	Medulloepithelioma				X
	Neuroblastoma				X
	Ependymoblastoma				X
	Atypical teratoid / rhaboid tumor				X
Cranial and nerve sheath tumors	Schwannoma	X			
	Neurofibroma	X			
	Malignant peripheral nerve sheath tumors			X	X

Tumor Group	Tumor Type	Grade I	Grade II	Grade III	Grade IV
Meningeal tumors	Meningioma	X			
	Atypical meningioma		X		
	Clear cell meningioma		X		
	Chordoid meningioma		X		
	Papillary meningioma			X	
	Rhabdoid meningioma			X	
	Anaplastic meningioma		X	X	
	Hemangiopericytoma				

After patient age, tumor histology and grade have been shown to be the strongest predictors of clinical course in selected CNS astrocytomas.^{2,24} Several grading systems for diffusely infiltrating astrocytomas have been proposed based on their ability to define distinct patient groups with significantly different survival curves. Both 3-tiered and 4-tiered systems are currently in use and have been reviewed.²⁵ Two examples of popular grading systems are shown below.²¹ For a complete review and comparison of these systems, including the 3-tiered system, such as Ringertz system and modifications thereof, the reader is referred to the review by McLendon et al.²⁵

Comparison of the WHO and St. Anne/Mayo Grading Systems for Astrocytomas²¹

WHO Grade	WHO Designation	St. Anne/Mayo Designation	Histologic Criteria
I	Pilocytic astrocytoma		
II	Astrocytoma (low-grade)	Astrocytoma, grade 2	1 criterion, usually nuclear atypia
III	Anaplastic astrocytoma	Astrocytoma, grade 3	2 criteria, usually nuclear atypia and mitoses
IV	Glioblastoma multiforme	Astrocytoma, grade 4	3 criteria, usually nuclear atypia, mitoses, and endothelial proliferation and/or necrosis

K. Other Pathologic Features

Hemosiderin deposition, calcification, and microcyst formation are nonspecific findings that occur in both malignant and benign CNS neoplasms. However, in general, calcification usually favors a slowly growing neoplasm, which is more likely to be benign.

In non-pilocytic neoplasms, the presence of gemistocytes, vascular proliferation, and necrosis represent negative prognostic indicators, and the latter 2 histologic changes are diagnostic of high-grade astrocytomas.^{10,26-28} By contrast, eosinophilic granular bodies typically occur in low grade neoplasms (pilocytic astrocytoma, ganglion cell tumors, and pleomorphic xanthoastrocytoma).⁴

Findings in Touch, Squash, or Scrape Preparations

The presence of process-forming cells is suggestive of a primary CNS neoplasm. Extreme fibrillarity may represent reactive astrocytosis.⁴ Touch or squash preparations are also of value in evaluating specimens for the presence of macrophages. A macrophage-rich lesion is more consistent with a subacute infarct or demyelinating lesion, rather than a tumor.

Local extension, rapid growth, invasion of adjacent structures, and CNS spread via the ventricular system or subarachnoid space are often suggestive of, but not always diagnostic of, malignancy. Low-grade neoplasms, such as meningioma and pilocytic astrocytoma, may also exhibit this type of spread, but at a slower rate of growth than most malignant tumors. Malignant and atypical meningeal tumors often invade brain substance.²⁹

References

1. Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. *J Clin Oncol*. 1997;15:3129-3140.
2. Wurschmidt F, Bunemann H, Heilmann HP. Prognostic factors in high-grade malignant glioma: a multivariate analysis of 76 cases with postoperative radiotherapy. *Strahlenther Onkol*. 1995;171:315-321.
3. Hirano H, Asakura T, Yokoyama S, et al. The prognostic factors in astrocytic tumors: analysis by the Kaplan-Meier method and the Weibull log-linear model. *No Shinkei Geka*. 1996;24:809-815.
4. Burger PC, Scheithauer B. Tumors of the central nervous system. In: *Atlas of Tumor Pathology*. Third Series. Fascicle 10. Washington, DC: Armed Forces Institute of Pathology; 1994.
5. Burger PC, Nelson JS. Stereotactic brain biopsies: specimen preparation and evaluation. *Arch Pathol Lab Med*. 1997;121:477-480.
6. Nitta T, Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. *Cancer*. 1995;75:2727-2731.
7. Lantos PL, Vandenberg SR, Kleihues P. Tumors of the nervous system. In: Graham DI, Lantos PL, eds. *Greenfield's Neuropathology*. Vol 1. 6th ed. New York, NY: Oxford University Press; 1997:125-126.
8. Lantos PL, Vandenberg SR, Kleihues P. Tumors of the nervous system. In: Graham DI, Lantos PL, eds. *Greenfield's Neuropathology*. Vol 2. 6th ed. New York, NY: Oxford University Press; 1997:586-587.
9. Jubelirer SJ. A review of the treatment and survival rates of 138 patients with glioblastoma multiforme. *W V Med J*. 1996;92:186-190.
10. Burger PC, Nelson JS, Boyko OB. Diagnostic synergy in radiology and surgical neuropathology: neuroimaging techniques and general interpretive guidelines. *Arch Pathol Lab Med*. 1998;122:609-619.
11. Burger PC, Nelson JS, Boyko OB. Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. *Arch Pathol Lab Med*. 1998;122:620-632.

12. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. *J Neurooncol.* 1996;27:65-73.
13. Fischbein NJ, Prados MD, Wara W, Russo C, Edwards MS, Barkovich AJ. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. *Pediatr Neurosurg.* 1996;24:9-23.
14. Rosenblum MK, Neuromuscular system. In: Rosai J. ed. *Ackerman's Surgical Pathology.* Vol. 2. 8th ed. St. Louis, Mo: Mosby-Year Book, Inc; 1996:2267-2268.
15. Prusiner SB, Bosque P. Prion diseases. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. *Harrison's Principles of Internal Medicine.* 15th ed. New York, NY: McGraw-Hill; 2001:2486-2491.
16. Compton CC, Harris NL, Ross DW. Protocol for the examination of specimens from patients with non-Hodgkin's lymphoma: a basis for checklists. *Arch Pathol Lab Med.* 1999;123:68-74.
17. Fuller GN, Hess KR, Rhee CH, Yung WKA, Sawaya RA, Bruner JM, Zhang W. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. *Brain Pathol.* 2002;12:108-116.
18. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". *J Neuropathol Exp Neurol.* 2002;61:58-63.
19. Snijders AM, Meijer GA, Brakenhoff RH, van den Brule AJ, van Diest PJ. Microarray techniques in pathology: tool or toy? *Mol Pathol.* 2000; 53:289-294.
20. Burger PC, Scheithauer BW, Lee RR, O'Neill BP. An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions. *Cancer.* 1997;80:2040-2046.
21. Kleihues P, Cavenee WK, eds. *Pathology and Genetics of Tumors of the Nervous System. World Health Organization Classification of Tumors.* Lyon, France: International Agency for Research on Cancer; 2000:6-7.
22. Greene FL, Page DL, Fleming ID, et al, eds. *AJCC Cancer Staging Manual.* 6th ed. New York: Springer; 2002:387-390.
23. Sobin LH, Wittekind C. *UICC TNM Classification of Malignant Tumours.* 6th ed. New York: Wiley-Liss; 2002.
24. Wakimoto H, Aoyagi M, Nakayama T, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. *Cancer.* 1996;77:373-380.
25. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM. Tumors of the central neuroepithelial origin. In: Bigner DD, McLendon RE, Bruner JM, eds. *Russell and Rubinstein's Pathology of Tumors of the Nervous System.* Vol. 1. 6th ed. New York, NY: Oxford University Press; 1998:311-314.
26. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. *Lab Invest.* 1997;76:277-284.
27. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. *Cancer.* 1996;77:362-372.
28. Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. *Cancer.* 1983;52:550-554.
29. McKeever PE, Burger PC, Nelson JS. Introduction to neurooncology. In: Nelson JS, Parisi JE, Schochet SS, eds. *Principles and Practice of Neuropathology.* St Louis, Mo: CV Mosby; 1993:109-122.

Bibliography

- Bigner SH, Johnson WW. *Cytopathology of the Central Nervous System*. 1st ed. Chicago, Ill: ASCP; 1994.
- Bigner DD, McLendon RE, Bruner JM, eds. *Russell and Rubinstein's Pathology of Tumors of the Nervous System*. 6th ed. New York, NY: Oxford University Press; 1998.
- Burger PC, Scheithauer B. *Tumors of the Central Nervous System. Atlas of Tumor Pathology*. Third Series. Fascicle 10. Washington, DC: Armed Forces Institute of Pathology; 1994.
- Burger PC, Scheithauer BW, Vogel FS. *Surgical Pathology of the Nervous System and its Coverings*. 4th ed. New York, NY: Churchill Livingstone; 2002.
- Kleihues P, Cavenee WK, eds. *Pathology and Genetics of Tumors of the Nervous System. World Health Organization Classification of Tumors*. Lyon, France: International Agency for Research on Cancer; 2000.
- Lantos PL, Vandenberg SR, Kleihues P. Tumors of the nervous system. In: Graham DI, Lantos PL, eds. *Greenfield's Neuropathology*. Vol 2. 6th ed. New York, NY: Oxford University Press; 1997:583-879.